There is a need for a more effective Developmental Neurotoxicity (DNT) screening which is scientifically driven by the fact that the developing nervous system might be more sensitive to exposures to some hazardous chemical. Additional concern comes from the recent societal concerns that toxic chemicals can contribute to the prevalence of neurodevelopment disabilities. Consequently, hazard identification and actions to reduce exposure to these chemicals is a priority in chemical risk assessment. To reach this goal a cost-efficient testing strategy based on a reliable in-vitro testing battery should be developed. Although this goal is representing a huge challenge in risk assessment, available data and methodologies are supporting the ultimate aim of developing a predictive model able to respond to different regulatory based problem formulations.
Introduction
There is concern among scientists and the public that exposure to chemicals is contributing in the development of certain neurological diseases and disorders. This concern is supported by a number of reported evidence that there is an increase in developmental disabilities including attention deficit hyperactivity disorder (ADHD), autism and learning disabilities. These complex disorders have multiple causes, such as genetic, social and environmental with a very high associated economic cost. (Grandjean and Landrigan, 2006; Grandjean and Landrigan, 2014; Smirnova et al., 2014; Gray and Billock, 2017; Boyle et al., 2011; Di Renzo et al., 2015; Gore et al., 2015; Lanphear, 2015; Chambers et al., 2004; Bellanger et al., 2015; Gould, 2009; Bennett et al., 2016) .
Although it is accepted that increased awareness and better diagnostics are important factors determining the increased prevalence of reported diagnoses of childhood psychiatric disorders (Atladottir et al., 2015; YooHJ, 2013; Getahun et al., 2013) , the contribution of environmental risk factors in adverse outcomes related to developmental neurotoxicity (DNT) remains a challenge for modern risk assessment. It is estimated that genetic factors account for no more than 30-40% of such disorders (NRC -National Research Council, 2007) and therefore there is concern that exposure to chemicals could have contributed to the observed increase in incidence. Indeed, for some chemicals a possible contribution to neurodevelopmental disorders is known, like for organophosphate pesticides, PBDE flame retardants, air pollutants, lead, mercury and PCBs, with evidence provided by epidemiological and toxicological studies (Bennett et al., 2016) .
It is however a challenge to show causation in epidemiological studies (EFSA, 2017a (EFSA, , 2017b . In particular, evidence of causation between exposure to non-persistent compounds such as most modern pesticides and adverse outcomes has proven to be relatively weak (Ntzani et al., 2013) and multiple factors, such as, among others, the inconsistency of findings, high heterogeneity, inappropriate documentation of exposure and lack of a more precisely determined trend over time in both children and adults, are limiting the use of epidemiological studies in a regulatory setting and for the definition of the relevant contributory factors to the diseases (EFSA, 2017a, b) .
Considering all these complexities, identifying and characterising hazards associated with the development of the nervous system is therefore key in chemical risk assessment. A number of scientific conferences and workshops on the need for more DNT testing have been held over the past decade. The consensus is that there is scientific evidence and health concerns that justify a regulatory need for more testing and that is therefore necessary to develop an effective strategy for a fit for purpose risk assessment of DNT (Bal-Price et al., 2015a) .
The need for a more effective DNT screening is scientifically driven by the fact that the developing nervous system might be very sensitive to exposures to some classes of hazardous chemical substances (Fritsche, 2017) . Moreover, there is in general a lack of understanding of DNT due to the paucity of tested chemicals; particularly tests performed in line with OECD-compliant in vivo guideline studies, which are the current standards for the identification and assessment of DNT hazardous chemicals.
The deficit in chemicals testing is due to a number of factors like: systematic testing for DNT is not a mandatory requirement, standard guideline studies are very resource intensive, in vivo regulatory studies are not intended to inform on mechanism of action.
For plant protection products (PPPs) -although the situation is similar for biocides -accepted guideline studies for DNT are not mandatory, but are triggered by observations in other studies or the mode of action of the pesticides. Often such observations become available from acute and repeated neurotoxicity studies where neurological effects, including structural, neuro-biochemical and behavioural effects, are expected to be captured and thus possibly trigger DNT data. Indications from developmental, multi-generation, acute and short-term neurotoxicity studies and, where performed, developmental neurotoxic effects will be relevant to conclude on the establishment of the regulatory reference doses -e.g. acute reference dose (ARfD) and acceptable daily intake(ADI).
In an analysis conducted by the JMPR (JMPR, 2002) of 14 pesticides evaluated by the US EPA, DNT-related toxicity endpoints were compared with effects retrieved from developmental, multi-generation, acute/short-term neurotoxicity studies. It was concluded that in general DNT studies were not used to identify lower points of departure (NOAELs and LOAELs) for the establishment of the regulatory reference doses.
Similarly, in a retrospective analysis of ARfDs for pesticides evaluated in the European Union (Solecki et al., 2010) , ARfDs based on DNT studies in rats represented 1% of the overall ARfDs. However, when considering the impact of DNT studies on the setting of ARfDs and ADIs, it should be noted that only 35 in-vivo DNT studies were conducted for the 485 pesticide active substances currently approved in the EU. Of these 35 studies, 19 were considered positive, with 18 showing evidence of both DNT and neurotoxicity. There was evidence of DNT in only one case, but no evidence of neurotoxicity was observed in adult animals.
In a comprehensive review made by Raffaele (Raffaele et al., 2010) , in 15 out of 72 pesticide active substances for which in vivo DNT testing was performed, the study was used to determine the point of departure for at least one risk assessment scenario. This indicates that DNT testing is relevant and sensitive though all the substances included in the analysis were considered neurotoxic; therefore, an understanding of DNT by other toxicity pathways is overall lacking. A conclusive summary suggests that although the majority of risk assessments can be considered protective in regard to in vivo DNT effects, in general DNT testing cannot be considered sufficient given the relatively low number of substances tested. Furthermore, if a similar evaluation is made globally in regard to health-hazard assessment of chemicals in general, the conclusion is even more substantiated .
This observed deficit in testing for DNT has been frequently associated with the methodological and scientific uncertainties of the in vivo studies. In vivo testing for DNT is currently based on studies (OECD TG 426 and OECD TG 443) intended to evaluate all developing life stages i.e. prenatal and postnatal periods up to puberty, by means of investigating gross neurological and behavioural abnormalities (including physical development), neuropathology and toxicokinetic (TK) endpoints. The protocols were, however, developed to be applicable to testing of any chemical and for this reason chemicals belonging to different regulatory frameworks could have undergone different testing. It should be noted that the methodologies for assessment of learning and memory are flexible, making it difficult to compare studies and findings. DNT guidelines studies are complex and very resource demanding (time and cost intensive) with raised concerns in terms of animal welfare. Interpretation of the results is frequently difficult, possibly due to lack of knowledge regarding brain development (Beronius et al., 2013) . Additional issues have been comprehensively described in a Scientific Opinion of the European Food Safety Authority (EFSA), Plant Protection Products and their Residues (PPR) Panel (EFSA, 2013) and they include excessive variability in results, difficulties to interpret minor statistically significant changes and to correctly interpret the findings in a complementary way. The Scientific Opinion is also quoting that a high level of expertise is necessary to assess the study results and evaluate their reliability and relevance for risk assessment. As most of the regulatory guideline studies, they are intended to explore and possibly capture hazards and are consequently conducted at high doses with the highest dose expected to be selected close to the maximum tolerated dose. However, the relevance for human exposure scenarios which is likely to be represented by exposure to low doses over prolonged time periods is questionable (Smirnova et al., 2014) and there is a limited understanding of impact of maternal toxicity (Kaufmann, 2003) . The predictivity for protection of the human brain is also questionable when considering differences in developmental timing and toxicodynamics between humans and rodents (Dorman et al., 2001; Kaufmann, 2003; Tsuji and Crofton, 2012) .
Although the current guideline studies are considered to represent the best available science for assessing the potential DNT in human risk assessment (Makris et al., 2009) , the sensitivity and reproducibility of in vivo testing is also questionable (Crofton et al., 2004; Smirnova et al., 2014; Bal-Price et al., 2015a) and, in some cases, negative or non-reproducible results have been observed with substances or mechanisms known to be of human concern, including methylmercury (Radonjic et al., 2013) or for substances acting on the hypothalamic-pituitary-thyroid (HPT) axis (European Commission, 2017) . Also importantly, extrapolation between the test species (rodents) and humans carries in this case substantial uncertainties due to: i) differences in TK and metabolism among species when taking sensitivity and reproducibility into account; ii) timing differences in brain development between rodents and humans; iii) use of non-homologous functional test, particularly in regard to cognitive performances; iv) and the fact that rodents do not capture or represent human relevant diseases such as for example autism, ADHD and Tourette's syndrome.
All these factors need to be carefully considered and weighted in order to develop a DNT testing strategy dependent on a regulatory context, based on the specific problem formulation and an acceptable level of uncertainties, to ultimately inform risk management decisions. It is therefore acceptable a different level of uncertainty when the problem formulation is intended to address testing for chemical screening and/or prioritisation or single substance hazard identification and characterization or mechanistic investigations.
For all these reasons discussed herein, consequently, DNT is regarded as an area where alternative methods should be developed to provide a scientifically validated, time-and cost-efficient testing strategy. In addition, understanding of the uncertainties associated with in vivo data is important when proposing testing strategies using in vitro assays or alternative animal models (e.g. zebra fish) and considering which validation approach to use. Indeed, a number of exemplary DNT test methods have been reported though some of them were not developed for regulatory use. A literature review was committed by EFSA with the goal of building a systematic and comprehensive literature search and data collection from past 20 years until mid-April 2014 on the state of the art of in vivo DNT testing methods including novel and alternative non-mammalian models, in vitro test methods, in silico methods, read across and combination of testing methods in test batteries (Fritsche et al., 2015) . The systematic review identified a variety of methods covering early and later stage of neurodevelopment with considerations on their ability to predict DNT of chemicals, definition of biological application domain, validation and protocol standardization needs.
Over the last decade a number of scientific initiatives have concluded that development of in vitro assays and other alternative methods could provide the basis for a non-in-vivo-based testing strategy to assess the impact of chemicals on DNT, and that such new test methods should be matched with the different regulatory needs (Bal- Price et al., 2015a Price et al., , 2015b . It is therefore important to understand what the scientific premises are, allowing a regulatory switch from a risk assessment based on identification of apical endpoints to a more mechanism-based risk assessment able to implement screening and prioritisation of chemicals for DNT or support a more tailored "fit for purpose" testing strategy for DNT.
The main elements that should be considered to match the alternative testing strategy with regulatory needs are: i) the identification of what represents an adverse outcome for DNT; ii) which mechanisms of toxicity can be explored using an alternative testing strategy; and iii) how to integrate the information into a "fit for purpose" regulatory problem formulation iv) establish DNT test and DNT test battery performance standards v) develop a testing strategy guidance by considering an integrated approach to testing and assessment (IATA).
If defining adversity seems to be complex for the in vivo DNT guideline, understanding what represents a toxicologically relevant effect is even more crucial for effects generated through alternative methods.
The development and use of adverse outcome pathways (AOPs) for DNT endpoints will increase confidence in the regulatory application of alternative methods to characterize key event relationships; identifying causative links between key events and adverse outcomes will increase the mechanistic understanding of the effects observed. In line with the OECD definition (OECD, 2012 (OECD, , 2014 an AOP is an analytical construct that describes a sequential chain of causally linked events, from a molecular initiating events (MIE) through a sequential series of key events (KEs) at different levels of biological organisation, that lead to an adverse health effect. AOPs are therefore the central element of a toxicological knowledge framework being built to support chemical risk assessment based on mechanistic reasoning.
A quantitative estimation will be further necessary for a more complete assessment of the perturbed pathway in order to avoid an overestimation of toxicity, which can potentially occur when only effects -rather than adverse outcomes -are considered. This approach has scientific validity and, importantly, is attractive from a regulatory perspective. However, although a number of AOPs have already been developed for DNT effects, it is ambitious to identify in a reasonable timeframe the multitude of remaining AOPs or to have a mechanistic understanding of the toxicities that can be explored by alternative testing strategies.
The discussion on these premises resulted in the conclusion that alternative methods should be focused on key cellular processes critical to normal brain development, including: neuronal and glial proliferation, differentiation, migration, neurite outgrowth, synaptogenesis, myelin formation, and neuronal network formation and function (Fritsche, 2017) . The basic assumption is that a perturbation of one of the fundamental biological processes of neurodevelopment will lead to an adverse outcome and that the above mentioned key events are common to many AOPs (Bal-Price et al., 2015b) .
From a strategic view, it is now necessary to come to a conclusive consensus on defining alternative methods to be assembled in a DNT testing battery and define the next steps for regulatory use. These steps should include additional experimental work as well as agreement of a harmonised and internationally accepted process. There was consensus by the participants of the OECD/EFSA workshop that such a draft framework for regulatory use of DNT data should be through an integrated approach to testing and assessment (IATA) driven by problem formulation in order to make efficient use of resources (Fritsche, 2017) .
With the ultimate goal of accelerating the development and regulatory use of an in vitro testing battery capable of cost-and time-efficient testing of chemicals for DNT, priority should be given to generating data using relevant chemicals for the purpose of performancebased validation. This should be followed by the development of data interpretation and use guidance, descriptions of possible application domains. Development of a number of case studies based on an IATA approach will be also necessary to indicated the best fitting of the testing battery and strategy.
As in any system of regulatory risk assessment and decision-making, there has to be high confidence in the data generated, and validation scrutiny is therefore not a trivial matter. It poses a scientific and regulatory challenge as for complex endpoints such as DNT it is difficult to define "true" results, particularly in relationship to human adverse outcomes, and also because extrapolation from animal models to human health outcomes is still uncertain in the absence of causative linkages. One possibility is to test a chemical library to challenge the battery and thereby lead to a mechanistic validation of the individual tests, as well as the entire battery. This is relevant because no single in vitro method would cover the full spectrum of DNT processes. In this perspective, data have been already generated (Aschner 2017; Mundy 2015) and being generated (Integrated Testing Strategies for Developmental Neurotoxicity, 2017) and it is now imperative to understand which compounds in the chemical library were tested, which gaps need to be filled and subsequently establish a prediction model to compare in-vitro results with knowledge from the in vivo-hazard. A critical step is therefore to build up a database of chemical compounds including positive controls, as well as a large number of negative controls. The database will keep track of tested compounds, negative or positive results and identify data gaps that need to be filled in terms of number of chemicals and key neurodevelopmental events e.g. migration assays, glial specific assays. A definition of the biological relevance of the pathway of toxicity explored by the test will be also necessary. The library should be large enough to allow computational comparison of assays that estimates the balanced accuracy of individual assays as well as batteries of assays.
Encouragingly, important steps have been taken towards this goal, making an alternative DNT testing strategy possibly ready for some regulatory use. These are:
• Libraries of reference chemicals for testing/challenging the different assays are being tested globally using both cellular models and zebrafish models (Nyffeler et al., 2017; Mundy et al., 2015; Aschner et al., 2017) .
• This is supported by the development of a database in which data from the library testing is deposited, allowing harmonised data analysis and evaluation. This also facilitates the identification of data gaps (Integrated Testing Strategies for Developmental Neurotoxicity, 2017).
• EFSA is initiating a project to generate data that will provide additional evidence for the regulatory suitability of an in vitro DNT testing battery.
• The OECD is developing complementary guidance for interpreting and integrating the data into regulatory decision making.
It is indeed crucial that more chemicals are tested. This is necessary in order to fill the gaps identified through the analysis of existing data on chemicals already been tested in assays that would contribute to a DNT testing battery. Additional testing should however avoid repetition and maximise synergisms across the involved partners. As already mentioned, it is important to increase the number of chemicals to be tested, particularly in the assays where so far only a limited number of compounds have been put through and in key neurodevelopmental events for which testing is actually lacking. Overall, the chemical library have to be enlarged to better understand/describe:
• the biological coverage of each test;
• how "fit-for-purpose" the methods are;
• the patterns across different assays; DNT chemotypes. A. Terron, S.H. Bennekou Toxicology and Applied Pharmacology 354 (2018) 19-23 
Conclusion
With an alarming increase in neurodevelopment disorders, it is necessary to re-think the way DNT is assessed and one crucial element is to understand the contribution of environmental chemicals through a correct identification and characterization of DNT related hazards. With the recognised lack of cost-efficient and rapid in vitro alternative assays for DNT, it is impossible to conduct an adequate screening for DNT potential and/or prioritize the large number of untested chemicals for further testing and risk assessment using existing in vivo methodologies; this represents a huge challenge in the risk assessment of chemicals.
Although the current DNT testing are not always satisfactory because of some uncertainties in their methodology, evaluation, and regulation, some uncertainties in the extrapolation from in vitro to in vivo are also existing, precluding a straightforward replacement of animal testing. However, data from more efficient in vitro models are available and should be considered for regulatory decisions.
In the US, similarly to what is being done for the Endocrine Disruption Screening Program, data from DNT in vitro models are expected to be considered for chemical prioritisation for further screening. This approach would represent a very helpful strategic change in the exploration of DNT hazardous substances and the development of in vitro alternative testing models. How such methods should be used for environmental risk assessment is of further critical relevance.
Indeed, multiple in-vitro and alternative animal models have been already developed over the last decade, but we are still suffering from a significant lack of data. It is crucial to prove the predictive utility of the different models, something that can be achieved by using a large number of environmental chemicals (Fritsche, 2017) . As a scientific consensus already exists, what we need now is to move on with testing to fill the gaps on methods performance, and regulatory acceptance of the methods. As it is clear that additional experimental work is needed, this needs an adequate financial support. Some initiatives are already in place so far sponsored by EFSA and it is also a specific goal of EUToxRisk (http://www.eu-toxrisk.eu/) funded by the European Union's Horizon 2020 research and innovation programme, but it is important to ensure a coordination of the experimental activities to avoid duplication and maximise synergism. In this perspective, the economical as well as the scientific activities would benefit of an international coordination which is feasible under the OECD umbrella and this is recommended.
EFSA, the US EPA and the Danish EPA are therefore committed to implementing the concepts and tools needed to identify DNT substances in an OECD remit. The ultimate aim is to build a predictive, valid and flexible model, able to respond to different regulatory-based problem formulations.
